8-K: NeuroOne Reports Strong Preliminary Q4 Revenue and Record Purchase Order

NeuroOne Medical Technologies Corporation announced preliminary unaudited financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2026, highlighting significant revenue growth and a record purchase order.

Summary

• NeuroOne Medical Technologies Corporation reported preliminary unaudited product revenue of approximately $3.8 million for the fourth fiscal quarter ended September 30, 2026, a 38.4% increase year-over-year.
• For the full fiscal year ended September 30, 2026, the company expects to report revenue of approximately $10.5 million, representing 15.6% year-over-year growth and reaching the top of its guidance range.
• The company secured a record $4.5 million product purchase order in September 2026.
• Approximately $1.0 million of the $4.5 million order shipped in September 2026.
• Shipments of the remaining $3.6 million from the large order are expected to commence in the first and second quarters of fiscal year 2027.
• As of September 30, 2026, total open purchase orders for shipments through the first quarter of fiscal year 2027 increased to $5.4 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with strong revenue growth and a significant purchase order indicating market traction and future revenue visibility.

Positives

• Achieved preliminary fiscal Q4 2026 product revenue of $3.8 million, a 38.4% increase year-over-year.
• Preliminary full-year fiscal 2026 product revenue reached $10.5 million, a 15.6% increase year-over-year, at the top of the guidance range.
• Secured a record $4.5 million product purchase order in September 2026.
• Total open purchase orders increased to $5.4 million as of September 30, 2026, providing strong visibility into fiscal year 2027 revenue.
• Product orders increased 24.2% in fiscal 2026 compared to fiscal 2025.
• The company is well-positioned for fiscal year 2027 with additional growth drivers including commercialization of its trigeminal neuralgia system, international market expansion, and advancement of its drug delivery platform.

Negatives

• The reported financial results are preliminary, unaudited, and subject to completion of year-end accounting and audit procedures, meaning they are subject to adjustment.
• Shipments of the majority of the large $4.5 million purchase order are scheduled for fiscal year 2027, not fully realized in the current reporting period.

Risks

• Risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements.
• Risks that strategic partnerships may not facilitate commercialization or market acceptance due to supply chain disruptions, labor shortages, or other factors.
• Risks that the technology will not perform as expected based on pre-clinical and clinical trial results.
• Risks related to uncertainties associated with the Company's capital requirements and ability to raise additional funds.
• Risk of not being able to secure or retain coverage or adequate reimbursement for the technology.
• Uncertainties inherent in the development process of the technology.
• Risks related to changes in regulatory requirements or decisions of regulatory authorities.
• Risks related to accurately estimating the size and growth potential of the markets for the technology.

Future Outlook

The company anticipates continued growth in fiscal year 2027, supported by $5.4 million in open purchase orders. Additional growth drivers include the commercialization of its trigeminal neuralgia system, international market expansion, and the advancement of its drug delivery platform. Shipments for the $4.5 million purchase order are expected to occur in Q1 and Q2 of fiscal year 2027.

Management Comments

• "Momentum continues to build across our business. We are happy to report that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. We enter fiscal 2027 from a position of strength supported by $5.4 million in open purchase orders and we are also very well positioned with additional growth drivers including the commercialization of our trigeminal neuralgia system, international market expansion, and the advancement of our drug delivery platform."
• Statement by Dave Rosa, Chief Executive Officer of NeuroOne.

Industry Context

StockSavvy.ai notes that NeuroOne's reported revenue growth and significant purchase order align with a positive trend in the medical technology sector, particularly for companies focused on specialized neurological treatments. The company's focus on minimally invasive technologies and expanding product families (cortical electrodes, sEEG electrodes, ablation systems) positions it to capitalize on the increasing demand for advanced surgical solutions.

Stakeholder Impact

• Shareholders: Potential for increased confidence and stock price appreciation due to strong revenue growth and a significant order backlog, though preliminary results are subject to audit.
• Employees: Positive impact from company growth and successful product commercialization, potentially leading to increased job security and opportunities.
• Customers: Benefit from the availability of advanced neurological treatment technologies and potential for improved surgical outcomes.
• Suppliers: Increased demand for materials and components to fulfill larger orders.
• Creditors: Improved financial health and cash flow visibility may strengthen the company's creditworthiness.

Next Steps

• Complete year-end accounting and audit procedures for fiscal year 2026.
• File the Company's Annual Report on Form 10-K with the Securities and Exchange Commission in December 2026.
• Announce complete financial results for the fourth quarter and full fiscal year 2026 in December 2026.
• Begin shipments of the remaining $3.6 million from the record purchase order during the first quarter of fiscal year 2027.
• Continue commercialization of the trigeminal neuralgia system.
• Pursue international market expansion.
• Advance the drug delivery platform.

Key Dates

Recommendation

The preliminary results show strong revenue growth and a significant purchase order, which are positive indicators. However, the results are unaudited and subject to change. The company also faces ongoing risks related to Nasdaq compliance, capital requirements, and market acceptance. Therefore, a 'hold' recommendation is appropriate pending the release of audited financial results and further clarity on the company's strategic execution and risk mitigation.

Keywords

medical technology, revenue, purchase order, fiscal year, product revenue, financial results, neurological disorders, guidance